Parkinson's disease: The effect of L-dopa therapy on urinary free catecholamines and metabolites

Annals of Clinical Biochemistry

Volumn 44, Issue 4, 2007, Pages 364-368

  Davidson, D F ^a   Grosset, K ^b   Grosset, D ^b  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; METADRENALIN; NORMETADRENALIN; ANTIPARKINSON AGENT; CREATININE; NORADRENALIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EXCRETION; DRUG URINE LEVEL; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; URINARY EXCRETION; URINE LEVEL; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; URINE;

ADOLESCENT; ADULT; AGED; ANTIPARKINSON AGENTS; CATECHOLAMINES; CREATININE; DOPAMINE; FEMALE; HOMOVANILLIC ACID; HUMANS; LEVODOPA; MALE; METANEPHRINE; MIDDLE AGED; NOREPINEPHRINE; NORMETANEPHRINE; PARKINSON DISEASE; PHEOCHROMOCYTOMA;

EID: 34548036766     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456307780945705     Document Type: Article

References (22)

1. Calne DB. Parkinsonism and other extrapyramidal diseases. In: Warrell DA, Cox TM, Firth JD, Benz Jr EJ, (Eds). Oxford Textbook of Medicine (4th edn). Oxford: Oxford University Press 2003; 3: 1053-8
2. Goodall M, Alton H. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects. Biochem Pharmac 1972; 21: 2401-8
3. Sandler M, Johnson RD, Ruthven CRJ, Reid JL, Calne DB. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature 1974; 247: 364-6
4. Routh JI, Bannow RE, Fincham RW, Stoll JL. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy. Clin Chem 1971; 17: 867-71
5. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003; 305: 800-11
6. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-49
7. Zendron L, Fehrenback J, Taverna C, Krause M. Pitfalls in the diagnosis of phaeochromocytoma. BMJ 2004; 328: 629-30
8. Davidson DF. Elevated urinary dopamine in adults and children. Ann Clin Biochem 2005; 42: 200-7
9. Davidson DF, Fitzpatrick J. A simple, optimised and rapid assay for urinary free catecholamines by HPLC with electrochemical detection. Ann Clin Biochem 1985; 22: 297-303
10. Davidson DF. Simultaneous assay for urinary 4-hydroxy-3-methoxy-mandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid by isocratic HPLC with electrochemical detection. Ann Clin Biochem 1989; 26: 137-43
11. Davidson DF. Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. Ann Clin Biochem 2002; 39: 557-66
12. Davidson DF. Paracetamol-associated interference in an HPLC-ECD assay for urinary free metadrenalines and catecholamines. Ann Clin Biochem 2004; 41: 316-20
13. Markianos M, Hadjikonstantinou M. Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: Effect of L-dopa treatment. Eur Neurol 1981; 20: 118-24
14. Markianos M, Hadjikonstantinou M, Bistolaki E. Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment. Acta Neurol Scand 1982; 66: 267-75
15. Barthelmebs M, Mbou P, Stephan D, Grima M, Imbs JL. Renal dopamine excretion in healthy volunteers after oral ingestion of L-dopa. Fundam Clin Pharmacol 1993; 7: 11-6
16. Dutton J, Copeland LG, Playfer JR, Roberts NB. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. Clin Chem 1993; 39: 629-34
17. Siirtola T, Sonninen V, Rinne UK. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. Clin Neurol Neurosurg 1975; 78: 77-88
18. Pisano JJ, Crout JR, Abraham D. Determination of 3-methoxy-4- hydroxymandelic acid in urine. Clin Chim Acta 1962; 7: 285-91
19. Factor SA, Schneider AS. Peripheral catecholamine output in Parkinson's disease: effects of drug treatment. Exp Neurol 1995; 131: 64-8
20. Pisano JJ. A simple analysis for normetanephrine and metanephrine in urine. Clin Chim Acta 1960; 5: 406-14
21. Bertani LM, Dziedzic SW, Clarke DD, Gitlow SE. A gas-liquid chromatographic method for the separation and quantitation of normetanephrine and metanephrine in human urine. Clin Chim Acta 1970; 30: 227-33
22. Boyle JG, Davidson DF, Connell JMC. Urinary free metadrenalines provide the best diagnostic biochemical test for phaeochromocytoma; experience in a tertiary care centre. Endocrine Abstracts 2004; 7: 85